...
首页> 外文期刊>Journal of Pharmaceutical and Biomedical Analysis: An International Journal on All Drug-Related Topics in Pharmaceutical, Biomedical and Clinical Analysis >Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes
【24h】

Mass spectrometric studies on the in vivo metabolism and excretion of SIRT1 activating drugs in rat urine, dried blood spots, and plasma samples for doping control purposes

机译:对大鼠尿,干燥血斑和等离子体样品中SIRT1活化药物体内代谢和排泄的质谱研究,用于掺杂控制目的

获取原文
获取原文并翻译 | 示例

摘要

The NAD+ depending enzyme SIRT1 regulates the mitochondrial biogenesis, fat and glucose metabolism through catalyzing the deacetylation of several metabolism-related protein-substrates. Recently, synthetic activators of SIRT1 referred to as STACs (Sirtuin activating compounds, e.g. SRT2104) were identified and tested in clinical studies for the treatment of aging-related diseases such as type 2 diabetes, Alzheimer's and obesity. Although the mechanism of SIRT1 activation by small molecules has caused considerable controversy, STACs demonstrated a significant performance enhancement in mice experiments including an improvement of endurance, muscle strength, and locomotor behavior. Due to their potential to increase exercise tolerance in healthy individuals, SIRT1 activators are currently being monitored by anti-doping authorities. In the present study, the in vivo metabolic clearance of three SIRT1 activators was investigated in rats by the collection of urine, DBS (dried blood spots) and plasma samples following a single oral administration. The resulting metabolic products were studied by positive electrospray ionization - (tandem) mass spectrometry and confirmed by the comparison with in vitro generated metabolites using human and rat liver microsomal preparations. Subsequently, a screening procedure for five SIRT1 activators and the metabolite M1-SRT1720 in DBS specimens was developed. Liquid-liquid-extraction and liquid chromatography/tandem mass spectrometry was employed based on diagnostic ion transitions recorded in multiple reaction monitoring mode and two deuterated internal standards namely d8-SRT1720 and d8-M1-SRT1720 were utilized. The doping control assay was characterized with regard to specificity, limit of detection (10-50ng/ml), recovery (65-83%) and imprecision (7-20%) and ion suppression/enhancement effects (10%), demonstrating its fitness-for-purpose for sports drug testing applications.
机译:NAD +依赖酶SIRT1通过催化几种与代谢相关的蛋白质 - 基质的脱乙酰化来调节线粒体生物发生,脂肪和葡萄糖代谢。最近,在临床研究中鉴定并测试SIRT1的SIRT1的合成活化剂(SRTUIN活化化合物,例如SRT2104),用于治疗衰老相关疾病,如2型糖尿病,阿尔茨海默氏症和肥胖症。虽然小分子的SIRT1激活的机制导致了相当大的争议,但Stacs在小鼠实验中表现出显着的性能增强,包括改善耐久性,肌肉力量和运动行为。由于他们有可能提高健康个体的运动耐受性,因此目前正在通过反兴奋剂机构监测SIRT1激活者。在本研究中,通过在单个口服给药后通过收集尿液,DBS(干血斑)和等离子体样品来研究三种SIRT1活化剂的体内代谢清除。通过阳性电喷雾电离 - (串联)质谱法研究了所得的代谢产物,并通过使用人和大鼠肝微粒体制剂与体外产生代谢物的比较证实。随后,开发了五种SIRT1活化剂的筛选程序和DBS样本中的代谢物M1-SRT1720。基于在多反应监测模式中记录的诊断离子转变使用液 - 液 - 萃取和液相色谱/串联质谱法,并且使用了两个氘代的内标,即D8-SRT1720和D8-M1-SRT1720。掺杂控制测定的特征在于特异性,检测限(10-50ng / ml),回收率(65-83%)和不精确(7-20%)和离子抑制/增强效应(& 10%),展示其适用于运动药物检测应用的适用性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号